JP7805783B2 - フッ素化胆汁酸誘導体 - Google Patents

フッ素化胆汁酸誘導体

Info

Publication number
JP7805783B2
JP7805783B2 JP2021529531A JP2021529531A JP7805783B2 JP 7805783 B2 JP7805783 B2 JP 7805783B2 JP 2021529531 A JP2021529531 A JP 2021529531A JP 2021529531 A JP2021529531 A JP 2021529531A JP 7805783 B2 JP7805783 B2 JP 7805783B2
Authority
JP
Japan
Prior art keywords
compound
ethyl
cholan
general formula
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021529531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533206A5 (enExample
JP2021533206A (ja
Inventor
チャールズ ウェイマウス‐ウイルソン アレクサンダー
パッカー ゲマ
ジャン ポル リンクラウ ブルーノ
キッド‐シンクレアー ダニエル
アン ワトソン キンバリー
Original Assignee
エヌゼットピー ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌゼットピー ユーケー リミテッド filed Critical エヌゼットピー ユーケー リミテッド
Publication of JP2021533206A publication Critical patent/JP2021533206A/ja
Publication of JP2021533206A5 publication Critical patent/JP2021533206A5/ja
Priority to JP2024038682A priority Critical patent/JP2024088648A/ja
Application granted granted Critical
Publication of JP7805783B2 publication Critical patent/JP7805783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021529531A 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体 Active JP7805783B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024038682A JP2024088648A (ja) 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1812382.8A GB201812382D0 (en) 2018-07-30 2018-07-30 Compounds
GB1812382.8 2018-07-30
PCT/GB2019/052127 WO2020025942A1 (en) 2018-07-30 2019-07-30 Fluorinated bile acid derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024038682A Division JP2024088648A (ja) 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体

Publications (3)

Publication Number Publication Date
JP2021533206A JP2021533206A (ja) 2021-12-02
JP2021533206A5 JP2021533206A5 (enExample) 2022-07-26
JP7805783B2 true JP7805783B2 (ja) 2026-01-26

Family

ID=63518053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021529531A Active JP7805783B2 (ja) 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体
JP2024038682A Pending JP2024088648A (ja) 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024038682A Pending JP2024088648A (ja) 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体

Country Status (7)

Country Link
US (1) US11517577B2 (enExample)
EP (1) EP3830103B8 (enExample)
JP (2) JP7805783B2 (enExample)
CN (1) CN112771063B (enExample)
ES (1) ES2968881T3 (enExample)
GB (1) GB201812382D0 (enExample)
WO (1) WO2020025942A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820887D0 (en) * 2018-12-20 2019-02-06 Nzp Uk Ltd Compounds
CN118660883A (zh) * 2021-11-15 2024-09-17 海湃泰克(北京)生物医药科技有限公司 多环化合物及其方法
CN115819491A (zh) * 2022-12-22 2023-03-21 江苏佳尔科药业集团股份有限公司 7-酮基石胆酸及熊去氧胆酸的合成方法
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083978A (zh) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
JP2017533923A (ja) 2014-11-06 2017-11-16 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
JP2018519246A (ja) 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2253593C (en) 1996-05-23 2008-07-08 Novartis Ag Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
AU2009316484B2 (en) 2008-11-19 2015-04-16 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN112057457A (zh) 2013-03-13 2020-12-11 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
WO2015085474A1 (zh) 2013-12-10 2015-06-18 华为终端有限公司 一种注册方法和相关节点以及注册系统
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
KR102526632B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN105348365A (zh) 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
JP2018507880A (ja) 2015-03-09 2018-03-22 インターセプト ファーマシューティカルズ， インコーポレイテッド 骨密度を調節する方法
CN107531741A (zh) 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸
US20160279393A1 (en) 2015-03-25 2016-09-29 Covidien Lp Guidewire retrieval catheter
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
TW201704251A (zh) 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
CN106210599B (zh) 2015-04-30 2021-02-12 中兴通讯股份有限公司 一种多画面调整方法、装置及多点控制单元
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
BR112018001869A2 (pt) 2015-07-30 2018-09-18 Intercept Pharmaceuticals Inc método para preparação de ácidos biliares e derivados dos mesmos
EP3331896A4 (en) 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
AU2016326428A1 (en) 2015-09-21 2018-04-12 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
CN108348533A (zh) 2015-11-06 2018-07-31 英特塞普特医药品公司 制备奥贝胆酸及其衍生物的方法
CA3009149A1 (en) 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
CN105646634A (zh) 2016-01-29 2016-06-08 中国药科大学 奥贝胆酸杂质的制备方法
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EA038632B1 (ru) 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533923A (ja) 2014-11-06 2017-11-16 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
CN106083978A (zh) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
JP2018519246A (ja) 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
EP3830103B1 (en) 2023-11-08
WO2020025942A1 (en) 2020-02-06
EP3830103B8 (en) 2023-12-20
GB201812382D0 (en) 2018-09-12
US20210299148A1 (en) 2021-09-30
CN112771063A (zh) 2021-05-07
CN112771063B (zh) 2023-10-27
ES2968881T3 (es) 2024-05-14
JP2021533206A (ja) 2021-12-02
EP3830103C0 (en) 2023-11-08
US11517577B2 (en) 2022-12-06
EP3830103A1 (en) 2021-06-09
JP2024088648A (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
JP2024088648A (ja) フッ素化胆汁酸誘導体
CN114786773B (zh) 苯并硫杂氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN106661079B (zh) 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
CN112449637B (zh) 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN108602811B (zh) Fxr受体激动剂
EP2019825B1 (en) Inhibitors of human immunodeficiency virus replication
CN105377870B (zh) 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
JP5269087B2 (ja) ヒト免疫不全ウイルス複製のインヒビター
TWI772289B (zh) 3-去氧基衍生物及其醫藥組成物與用途
JP5269085B2 (ja) ヒト免疫不全ウイルス複製のインヒビター
WO2023143400A1 (zh) 甾类化合物、其制备方法和应用
US20200131144A1 (en) Amine or (thio)amide containing lxr modulators
Ding et al. Andrographolide derivative as antagonist of vitamin D receptor to induce lipidation of microtubule associate protein 1 light chain 3 (LC3)
HK40055914A (en) Fluorinated bile acid derivatives
HK40055914B (en) Fluorinated bile acid derivatives
EP3658566A2 (en) Side-chain modified ergosterol and stigmasterol derivatives as liver x receptor modulators
KR20210045390A (ko) Fxr 수용체 작용제로서 이속사졸
EP3160508B1 (en) Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer
RU2785867C9 (ru) Бензотиа(ди)азепины и их применение в качестве модуляторов желчных кислот
RU2785867C2 (ru) Бензотиа(ди)азепины и их применение в качестве модуляторов желчных кислот
Chen et al. Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists
EP4583874A1 (en) Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases
HK1131153B (en) Inhibitors of human immunodeficiency virus replication
HK1221471B (en) 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7805783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150